Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19

A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial role of low molecular weight heparin (LMWH), but the optimal dosage of this treatment is unknown. We evaluated the associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mennuni, Marco G., Renda, Giulia, Grisafi, Leonardo, Rognoni, Andrea, Colombo, Crizia, Lio, Veronica, Foglietta, Melissa, Petrilli, Ivan, Pirisi, Mario, Spinoni, Enrico, Azzolina, Danila, Hayden, Eyal, Aimaretti, Gianluca, Avanzi, Gian Carlo, Bellan, Mattia, Cantaluppi, Vincenzo, Capponi, Andrea, Castello, Luigi M., D’Ardes, Damiano, Corte, Francesco Della, Gallina, Sabina, Krengli, Marco, Malerba, Mario, Pierdomenico, Sante D., Savoia, Paola, Zeppegno, Patrizia, Sainaghi, Pier P., Cipollone, Francesco, Patti, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919624/
https://www.ncbi.nlm.nih.gov/pubmed/33649979
http://dx.doi.org/10.1007/s11239-021-02401-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919624/
https://www.ncbi.nlm.nih.gov/pubmed/33649979
http://dx.doi.org/10.1007/s11239-021-02401-x

Ejemplares similares